Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study

Authors

Institutions

Publication Details

Journal
Annals of the Rheumatic Diseases
Published
2024-08-19
DOI
https://doi.org/10.1136/ard-2024-225686
Citations
42
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
18.33

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study

Paul P. Tak, Murray B. Urowitz, Ronald van Vollenhoven, Don Shanahan et al.
42 citations
Annals of the Rheumatic Diseases
Systemic Lupus Erythematosus Research
18.33
article

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study

Paul P. Tak, Murray B. Urowitz, Ronald van Vollenhoven, Don Shanahan, Mary Oldham, Cornelia F Allaart, Cynthia Aranow, Yun Irene Gregan, W. Winn Chatham, James Groark, Kenneth L. Clark, Robert B. Henderson, David A. Roth, Zahir Amoura, Patricia C Cagnoli, Mark Daniels, Ian N Bruce, André van Maurik, Josephine C Ocran-Appiah, Richard Alan Furie, Y K Onno Teng, Norma Lynn Fox
article en
42 citations

Abstract

No abstract available for this paper.
Annals of the Rheumatic DiseasesVol. 83(11)
Northwell Health (US), Feinstein Institute for Medical Research (US), Inserm (FR), University of Toronto (CA), University of Michigan (US), Toronto Western Hospital (CA), Manchester Academic Health Science Centre (GB), Leiden University Medical Center (NL), Age UK (GB), University of Manchester (GB), University of Alabama at Birmingham (US), Sorbonne Université (FR), Assistance Publique – Hôpitaux de Paris (FR), GlaxoSmithKline (United States) (US), Centre d'Immunologie et des Maladies Infectieuses (FR)
Medical Research Council
Good health and well-being
Openalex Percentile: Top 0%
Systemic Lupus Erythematosus Research
18.33
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.